ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO444

Plasma B Cell-Activating Factor (BAFF) Levels Predict the Upcoming Depressive Symptoms in Hemodialysis Patients

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis


  • Jang, Woojin, Veterans Healthcare Service Medical Center, Seoul, Korea (the Republic of)
  • Lee, Dong-Young, Veterans Healthcare Service Medical Center, Seoul, Korea (the Republic of)

B cell activating factor (BAFF) is a cytokine that plays a role in B cells’ maturation, homeostasis, and differentiation and is associated with mental disorders. Depression can often be caused by inflammation, with various cytokines playing a role. Chronic inflammation is common in hemodialysis (HD) patients, and depression is also prevalent among them. We hypothesize that BAFF may predict upcoming depressive symptoms in HD patients, so we evaluated their association.


Among 643 subjects who enrolled in a multi-center prospective HD cohort study, we investigated 72 patients who tested plasma BAFF levels, performed initial and follow-up Beck Depression Inventory, and had no depressive symptoms at first. We conducted a univariate and multivariate Cox regression analysis to calculate the hazard ratio (95% confidence interval (CI)) between upcoming depressive symptoms and BAFF levels.


In both univariate and multivariate analyses, a 1 standard deviation (SD) increase in BAFF was significantly linked with a higher risk of future depressive symptoms. The HR was 1.437 (95% CI 1.034-1.996) and 1.699 (95% CI 1.037-2.784), respectively. Patients with higher BAFF levels experienced more depressive symptoms than those with lower BAFF levels for 2 years (p = 0048).


In HD patients, elevated levels of plasma BAFF showed a significant association with depressive symptoms up to two years later.

Hazard ratios of plasma BAFF and APRIL for depressive symptoms
 HR95% CIHR95% CI

Table 1. The baseline characteristics of all subjects and with or without depressive symptoms